skip to primary navigationskip to content

Dr David Jayne

Dr David Jayne

David Jayne is accepting applications for PhD students.

Research Interests

Clinical evaluation of newer immunotherapeutics in vasculitis, lupus and immune-mediated renal disease. Co-ordination of international clinical research vasculitis network (EUVAS) and multi-centre randomised controlled trials. Development of clinical trial methodology, management guidelines and implementation of best clinical practice. Support of genetic, gene expression and biomarker studies


clinical trials ; B cells ; monoclonal antibodies ; immunotherapy ; human studies ; clinical immunology ; antibody engineering


  • systemic lupus erythematosus
  • autoimmunity
  • renal disease
  • vasculitis
  • Wegener's granulomatosis
  • immunodeficiency - secondary
  • rheumatic disease

Key Publications

Wallin EF, Jolly EC, Suchánek O, Bradley JA, Espéli M, Jayne DR, Linterman MA, Smith KG.Human T follicular helper and T follicular regulatory cell maintenance is independent of germinal centers. Blood. 2014 Sep 15. pii: blood-2014-07-585976.

Walsh M, Faurschou M, Berden A, Flossmann O, Bajema I, Hoglund P, Smith R, Szpirt W, Westman K, Pusey CD, Jayne DR; European Vasculitis Study Group. Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1571-6. d

Marco H, Smith RM, Jones RB, Guerry MJ, Catapano F, Burns S, Chaudhry AN, Smith KG, Jayne DR. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord. 2014;15:178.

Furuta S, Chow YW, Chaudhry AN, Jayne D. Switching of anti-TNF-α agents in Behçet's disease. Clin Exp Rheumatol. 2012 Sep 25.

Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L, Gunnarsson I, Harper L, Hrušková Z, Little MA, Martorana D, Neumann T, Ohlsson S, Padmanabhan S, Pusey CD, Salama AD, Sanders JS, Savage CO, Segelmark M, Stegeman CA, Tesař V, Vaglio A, Wieczorek S, Wilde B, Zwerina J, Rees AJ, Clayton DG, Smith KG. Genetically distinct subsets within ANCA-associated vasculitis N Engl J Med. 2012 Jul 19;367(3):214-23

Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, Smith KG, Jayne DR. Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis Rheum. 2012 Jun 21.

Smith RM, Jones RB, Jayne DR. Progress in treatment of ANCA-associated vasculitis. Arthritis Res Ther. 2012 Apr 30;14(2):210.

Guerry MJ, Brogan P, Bruce IN, D'Cruz DP, Harper L, Luqmani R, Pusey CD, Salama AD, Scott DG, Savage CO, Watts RA, Jayne DR. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012 Apr;51(4):634-43.

Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211–220.